To update the prescribing information for tarlatamab-dlle (IMDELLTRA) regarding monitoring requirements in patients with extensive-stage small cell lung cancer.
Approach:
Monitoring Update: The FDA reduced the recommended monitoring time following the first two doses from 22-24 hours to 6-8 hours.
Post-Dose Assessment: An assessment, including vital signs, is required the day after each of the first two doses.
Ongoing Monitoring: Monitoring remains 6-8 hours after the third dose and decreases progressively in subsequent cycles.
Key Findings:
Cytokine release syndrome occurred in 57% of a pooled safety population of 473 patients.
Neurologic toxicity was reported in 65% of patients.
Boxed warnings include cytokine release syndrome and neurologic toxicity.
Interpretation:
The revised monitoring guidelines aim to enhance patient safety while receiving tarlatamab.
Limitations:
The update applies only to the first two doses of tarlatamab.
Safety data is based on a pooled population and may not represent all patients.
Conclusion:
The FDA's update reflects a significant change in monitoring protocols for tarlatamab administration.
Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.
